Tin tức & Cập nhật

Fracture risk not higher with SGLT2 vs DPP4 inhibitors
Fracture risk not higher with SGLT2 vs DPP4 inhibitors
19 Feb 2023

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

Fracture risk not higher with SGLT2 vs DPP4 inhibitors
19 Feb 2023
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
18 Feb 2023

Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.

Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
18 Feb 2023
Rising cases of community-acquired E. coli UTI in children a cause for concern
Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023

A recent study has found an increasing prevalence of community-acquired (CA) urinary tract infection (UTI) by emerging spectrum-β-lactamase-producing (ESBL) E. coli in children, with most isolates showing resistance to multiple drugs.

Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023